Background: Depression and anxiety coexist with Alzheimer's disease (AD) and Parkinson's disease (PD), yet their progression trajectories vary, necessitating a thorough examination of prescription patterns for antidepressants and anti-anxiety drugs pre- and post-diagnosis.
Objectives: To systematically compare the prescriptions of antidepressant and anti-anxiety drugs across AD and PD over 10 years before and after initial diagnosis in the UK and France.
Methods: Data on 19,954 patients with AD, 25,267 with PD from the UK, 17,463 with AD, 10,333 with PD from France were extracted from The Health Improvement Network database.
medRxiv
January 2025
Background: Leveraging machine learning on electronic health records offers a promising method for early identification of individuals at risk for dementia and neurodegenerative diseases. Current risk algorithms heavily rely on age, highlighting the need for alternative models with strong predictive power, especially at age 65, a crucial time for early screening and prevention.
Methods: This prospective study analyzed electronic health records (EHR) from 76,427 adults (age 65, 52.
Background: The Banff Classification may not adequately address protocol transplant biopsies categorized as normal in patients experiencing unexplained graft function deterioration. This study seeks to employ convolutional neural networks to automate the segmentation of glomerular cells and capillaries and assess their correlation with transplant function.
Methods: A total of 215 patients were categorized into three groups.
Nephrol Dial Transplant
November 2023
Background: Interstitial inflammation and peritubular capillaritis are observed in many diseases on native and transplant kidney biopsies. A precise and automated evaluation of these histological criteria could help stratify patients' kidney prognoses and facilitate therapeutic management.
Methods: We used a convolutional neural network to evaluate those criteria on kidney biopsies.
Background: The identification of modifiable risk factors for Alzheimer's disease is paramount for early prevention and the targeting of new interventions. We aimed to assess the associations between health conditions diagnosed in primary care and the risk of incident Alzheimer's disease over time, up to 15 years before a first Alzheimer's disease diagnosis.
Methods: In this agnostic study of French and British health records, data from 20 214 patients with Alzheimer's disease in the UK and 19 458 patients with Alzheimer's disease in France were extracted from The Health Improvement Network database.
Neurobiol Aging
September 2021
Combining multimodal biomarkers could help in the early diagnosis of Alzheimer's disease (AD). We included 304 cognitively normal individuals from the INSIGHT-preAD cohort. Amyloid and neurodegeneration were assessed on F-florbetapir and F-fluorodeoxyglucose PET, respectively.
View Article and Find Full Text PDFFront Psychiatry
December 2020
We ranked third in the Predictive Analytics Competition (PAC) 2019 challenge by achieving a mean absolute error (MAE) of 3.33 years in predicting age from T1-weighted MRI brain images. Our approach combined seven algorithms that allow generating predictions when the number of features exceeds the number of observations, in particular, two versions of best linear unbiased predictor (BLUP), support vector machine (SVM), two shallow convolutional neural networks (CNNs), and the famous ResNet and Inception V1.
View Article and Find Full Text PDFWe performed a systematic review of studies focusing on the automatic prediction of the progression of mild cognitive impairment to Alzheimer's disease (AD) dementia, and a quantitative analysis of the methodological choices impacting performance. This review included 172 articles, from which 234 experiments were extracted. For each of them, we reported the used data set, the feature types, the algorithm type, performance and potential methodological issues.
View Article and Find Full Text PDFWe propose a method for recruiting asymptomatic Amyloid positive individuals in clinical trials, using a two-step process. We first select during a pre-screening phase a subset of individuals which are more likely to be amyloid positive based on the automatic analysis of data acquired during routine clinical practice, before doing a confirmatory PET-scan to these selected individuals only. This method leads to an increased number of recruitments and to a reduced number of PET-scans, resulting in a decrease in overall recruitment costs.
View Article and Find Full Text PDF